Payment overview · 2025
General Payments
$1,639.51
69 reported records · 25 companies
Healthcare provider profile · identity verified
Scott R Heilmann, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PANAMA CITY BEACH, FL · NPI 1164875894
Verified facts
What the public records show
CMS Open Payments records show Scott R Heilmann, ARNP received $1,639.51 in general payments during 2025 across 69 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $242.20 | 14.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.37 | 9.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $139.67 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $129.85 | 7.9% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $115.68 | 7.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.49 | 6.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.83 | 4.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.63 | 4.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.80 | 4.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $60.19 | 3.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.55 | 3.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.05 | 3.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.92 | 2.5% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $39.91 | 2.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.45 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.06 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.94 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.83 | 2.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.18 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.10 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.95 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.73 | 1.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.75 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.91 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.47 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,639.51 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.65 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $139.67 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.05 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.85 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $115.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.49 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.63 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.52 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.80 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.59 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.55 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $52.05 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.92 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.45 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 208 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 40 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 524 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 458 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 100 |
| Donepezil Hcl | Donepezil Hcl | 341 | 53 |
| Gabapentin | Gabapentin | 293 | 78 |
| Memantine Hcl | Memantine Hcl | 271 | 48 |
| Carvedilol | Carvedilol | 263 | 74 |
| Losartan Potassium | Losartan Potassium | 260 | 81 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 235 | 94 |
| Omeprazole | Omeprazole | 232 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 60 |
| Lisinopril | Lisinopril | 231 | 74 |
| Sertraline Hcl | Sertraline Hcl | 223 | 59 |
| Eliquis | Apixaban | 208 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 55 |
| Famotidine | Famotidine | 180 | 56 |
| Potassium Chloride | Potassium Chloride | 179 | 50 |
| Furosemide | Furosemide | 175 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 39 |
| Valsartan | Valsartan | 175 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 93 |
| Montelukast Sodium | Montelukast Sodium | 169 | 62 |
| Metformin Hcl | Metformin Hcl | 159 | 52 |
| Prednisone | Prednisone | 156 | 95 |
| Mirtazapine | Mirtazapine | 151 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 59 |
| Doxycycline Hyclate | Doxycycline Hyclate | 139 | 115 |
| Alprazolam | Alprazolam | 138 | 36 |
| Buspirone Hcl | Buspirone Hcl | 132 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 34 |
| Tramadol Hcl | Tramadol Hcl | 120 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 27 |
| Trazodone Hcl | Trazodone Hcl | 115 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 29 |
| Spironolactone | Spironolactone | 111 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 40 |
| Simvastatin | Simvastatin | 99 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 97 | 57 |
| Methylprednisolone | Methylprednisolone | 94 | 82 |
| Meloxicam | Meloxicam | 93 | 36 |
| Ezetimibe | Ezetimibe | 91 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 21 |
| Azithromycin | Azithromycin | 87 | 62 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 87 | 30 |
| Allopurinol | Allopurinol | 85 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | 29 |
| Levetiracetam | Levetiracetam | 84 | 15 |
| Bupropion Xl | Bupropion Hcl | 80 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 52 |
| Mounjaro | Tirzepatide | 73 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 16 |
| Clonazepam | Clonazepam | 66 | 17 |
| Myrbetriq | Mirabegron | 65 | 17 |
| Celecoxib | Celecoxib | 61 | 24 |
| Januvia | Sitagliptin Phosphate | 59 | 19 |
| Sucralfate | Sucralfate | 58 | 18 |
| Clonidine Hcl | Clonidine Hcl | 57 | 33 |
| Cefdinir | Cefdinir | 56 | 46 |
| Eszopiclone | Eszopiclone | 56 | 13 |
| Lorazepam | Lorazepam | 55 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 28 |
| Risperidone | Risperidone | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 21 |
| Mupirocin | Mupirocin | 51 | 42 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 50 | suppressed |
| Cephalexin | Cephalexin | 48 | 39 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 29 |
| Fluconazole | Fluconazole | 44 | 33 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 14 |
| Nystatin | Nystatin | 41 | 25 |
| Amoxicillin | Amoxicillin | 38 | 36 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 13 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 28 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 22 |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 17 |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | 11 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,639.51 · 69 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VIVITROL, VOQUEZNA, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error